Asahi Kasei Pays Auxilium $15 Million For Xiaflex Rights In Japan
This article was originally published in PharmAsia News
Executive Summary
Asahi Kasei Pharma has agreed to pay $15 million upfront to Auxilium Pharmaceuticals for exclusive rights to commercialize Xiaflex (collagenase clostridium histolyticum) in Japan